Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BTIG Maintains Buy on Stryker, Lowers Price Target to $232

BTIG analyst Ryan Zimmerman maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $238 to $232.

byBenzinga Newsdesk

October 17, 2022

1 minute read

BTIG analyst Ryan Zimmerman maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $238 to $232.

Marine Products Reveals Several Senior Leadership Changes

By Shivani Kumaresan

Today, 5:55 AM

Marine Products Corp (NYSE:MPX) has promoted its CFO, Ben M. Palmer, to assume the roles of President and CEO, effective immediately.…

MPX

GSK Pulls Plug On Late-Stage Asset Under Development For Rheumatoid Arthritis

By Vandana Singh

Today, 5:55 AM

GSK plc (NYSE:GSK) has issued an update on the ContRAst phase 3 program for otilimab, an investigational monoclonal antibody for moderate…

GSK

Wells Fargo Maintains Equal-Weight on Wynn Resorts, Lowers Price Target to $101

By Benzinga Newsdesk

Today, 5:55 AM

Wells Fargo analyst Daniel Politzer maintains Wynn Resorts (NASDAQ:WYNN) with a Equal-Weight and lowers the price target from $112 to $101.

WYNN

Teva Recalls One Batch Of Topotecan After Complaint Of Glass Particulate In Vial

By Vandana Singh

Today, 5:55 AM

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is recalling one lot of its cancer drug topotecan injection after a pharmacy complaint flagged the presence of a single glass particulate in a vial of the drug.

TEVA

BTIG Maintains Buy on Stryker, Lowers Price Target to $232

Related Posts

Marine Products Reveals Several Senior Leadership Changes

GSK Pulls Plug On Late-Stage Asset Under Development For Rheumatoid Arthritis

Wells Fargo Maintains Equal-Weight on Wynn Resorts, Lowers Price Target to $101

Teva Recalls One Batch Of Topotecan After Complaint Of Glass Particulate In Vial